OncoMatch/Clinical Trials/NCT04342910
Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC
Is NCT04342910 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including camrelizumab and Apatinib Mesylate for gastric cancer.
Treatment: camrelizumab · Apatinib Mesylate · Paclitaxel · Irinotecan — This is a study for participants with advanced gastric or gastroesophageal junction adenocarcinoma who have had tumor progression after first-line platinum-contained therapy. The primary study hypotheses are that camrelizumab (SHR-1210) combined with apatinib prolongs overall survival (OS) for participants with tumors that show positive programmed cell death ligand 1 (PD-L1) expression.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Chemotherapy
Cancer type
Gastric Cancer
Biomarker criteria
Required: PD-L1 (CD274) any tested (testing required; no eligibility threshold specified)
Willing to provide tumor tissue for PD-L1 biomarker analysis
Allowed: HER2 (ERBB2) positive
HER-2/neu status known and participants with HER2/neu positive tumors show documentation of previous treatment containing trastuzumab
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: platinum-based chemotherapy — first-line
Progression on or after prior first-line therapy containing any platinum/fluoropyrimidine or platinum/taxane doublet
Cannot have received: anti-PD-1 therapy
Subjects who have previously received anti-PD-1 / PD-L1 monoclonal antibody
Cannot have received: anti-PD-L1 therapy
Subjects who have previously received anti-PD-1 / PD-L1 monoclonal antibody
Cannot have received: anti-CTLA-4 therapy
Subjects who have previously received anti-CTLA-4 monoclonal antibody
Cannot have received: VEGFR inhibitor
Subjects who have previously received ... VEGFR small molecule inhibitor therapy
Cannot have received: systemic chemotherapy
Exception: within 4 weeks before the study drug administration
Prior systemic chemotherapy, radiotherapy and surgery within 4 weeks before the study drug administration
Cannot have received: radiation therapy
Exception: within 4 weeks before the study drug administration
Prior systemic chemotherapy, radiotherapy and surgery within 4 weeks before the study drug administration
Cannot have received: surgery
Exception: within 4 weeks before the study drug administration
Prior systemic chemotherapy, radiotherapy and surgery within 4 weeks before the study drug administration
Lab requirements
Blood counts
Kidney function
Liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04342910 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior anti-PD-1 therapy, anti-PD-L1 therapy, anti-CTLA-4 therapy disqualifies patients from enrollment.
Does this trial require CD274?
Yes, CD274 any tested is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages